Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TET2 | Q6N021 | 3/20 | 0.94 |
| ▸ | KDM4A | O75164 | 2/20 | 0.94 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.94 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.94 |
| ▸ | TET3 | O43151 | 1/20 | 0.94 |
| ▸ | FOLH1 | Q04609 | 7/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | GRM8 | O00222 | 1/20 | 0.50 |
| ▸ | GRM6 | O15303 | 1/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.50 |
| ▸ | GSR | P00390 | 1/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.50 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.50 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28597065 | 1.00 | TET2 (0.94) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL20598827 | 1.00 | TET2 (0.94) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL1614089 | 1.00 | TET2 (0.94) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL28200341 | 1.00 | TET2 (0.94) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL29844290 | 0.97 | TET2 (1.00) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL7509 | 0.97 | TET2 (1.00) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL8032 | 0.97 | TET2 (1.00) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL31620639 | 0.97 | TET2 (1.00) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL864236 | 0.97 | TET2 (1.00) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL465914 | 0.97 | TET2 (1.00) | TET2KDM4AKDM4CKDM2ATET3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109417016-A | For treating the glutaric acid compound of ischemia reperfusion injury | 加州大学董事会 | 2019-03-01 | — | — | CN | claimed |
| CN-117701571-A | Novel D-2-hydroxyglutarate nucleic acid aptamer and screening and verifying method | 南京师范大学 | 2024-03-15 | — | — | CN | disclosed |
| US-11007163-B2 | Glutarate compounds for treating ischemia-reperfusion injuries | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200253907-A1 | Compositions and Methods for Treating Neurodegenerative Diseases | UNIV CALIFORNIA (US) | 2020-08-13 | — | — | US | disclosed |
| EP-3672583-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | The Regents of the University of California (US) | 2020-07-01 | — | — | EP | disclosed |
| US-20200069621-A1 | Glutarate Compounds for Treating Ischemia-Reperfusion Injuries | UNIV CALIFORNIA (US) | 2020-03-05 | — | — | US | disclosed |
| US-10500177-B2 | Glutarate compounds for treating ischemia-reperfusion injuries | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-12-10 | — | — | US | disclosed |
| US-20190201357-A1 | Glutarate Compounds for Treating Ischemia-Reperfusion Injuries | UNIV CALIFORNIA (US) | 2019-07-04 | — | — | US | disclosed |
| CN-109803647-A | α-batanone acid, α-ketoglutaric acid and 2- hydroxybutyric acid are for stimulating hair growth | 加州大学董事会 | 2019-05-24 | — | — | CN | disclosed |
| US-10285962-B2 | Glutarate compounds for treating ischemia-reperfusion injuries | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-05-14 | — | — | US | disclosed |
| EP-3453046-A1 | GLUTARATE COMPOUNDS FOR TREATING ISCHEMIA-REPERFUSION INJURIES | The Regents of the University of California (US) | 2019-03-13 | — | — | EP | disclosed |
| CN-109417016-A | For treating the glutaric acid compound of ischemia reperfusion injury | 加州大学董事会 | 2019-03-01 | — | — | CN | disclosed |
| WO-2019038655-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-02-28 | — | — | WO | disclosed |
| US-20170333373-A1 | Glutarate Compounds for Treating Ischemia-Reperfusion Injuries | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-11-23 | — | — | US | disclosed |
| WO-2017192413-A1 | GLUTARATE COMPOUNDS FOR TREATING ISCHEMIA-REPERFUSION INJURIES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069621-A1 | Glutarate Compounds for Treating Ischemia-Reperfusion Injuries | GCDH, OGDH, GLS | TET2 2614/4885KDM4A 1579/4885KDM4C 1960/4885 |
| US-20190201357-A1 | Glutarate Compounds for Treating Ischemia-Reperfusion Injuries | GCDH, OGDH, GLS | TET2 2614/4885KDM4A 1579/4885KDM4C 1960/4885 |
| US-11007163-B2 | Glutarate compounds for treating ischemia-reperfusion injuries | GCDH, OGDH, GLS | TET2 2614/4885KDM4A 1579/4885KDM4C 1960/4885 |
| US-20200253907-A1 | Compositions and Methods for Treating Neurodegenerative Diseases | SNCA, PSEN2, PSEN1 | TET2 3080/4885KDM4A 3114/4885KDM4C 2988/4885 |
| US-20170333373-A1 | Glutarate Compounds for Treating Ischemia-Reperfusion Injuries | GCDH, OGDH, GLS | TET2 2614/4885KDM4A 1579/4885KDM4C 1960/4885 |
| US-10500177-B2 | Glutarate compounds for treating ischemia-reperfusion injuries | GCDH, OGDH, GLS | TET2 2614/4885KDM4A 1579/4885KDM4C 1960/4885 |
| US-10285962-B2 | Glutarate compounds for treating ischemia-reperfusion injuries | GCDH, OGDH, GLS | TET2 2614/4885KDM4A 1579/4885KDM4C 1960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.